LONDON, June 12 /PRNewswire/ -- Key trends are occurring within pharma-biotech alliances, as well within biotech-biotech alliances. With pharma companies experiencing weak R&D pipelines and biotechnology companies grappling with funding shortfalls, strategic alliances are being wielded as a tool for survival. Even as the frequency of earlier stage development deals increases, effective management will be necessary to ensure that such alliances are successful.
